Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
Abstract
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in lethal metastatic prostate cancers and the development of a STEAP1-directed chimeric antigen receptor (CAR) T cell therapy. STEAP1 CAR T cells demonstrate reactivity in low antigen density, antitumor activity across metastatic prostate cancer models, and safety in a human STEAP1 knock-in mouse model. STEAP1 antigen escape is a recurrent mechanism of treatment resistance and is associated with diminished tumor antigen processing and presentation. The application of tumor-localized interleukin-12 (IL-12) therapy in the form of a collagen binding domain (CBD)-IL-12 fusion protein combined with STEAP1 CAR T cell therapy enhances antitumor efficacy by remodeling the immunologically cold tumor microenvironment of prostate cancer and combating STEAP1 antigen escape through the engagement of host immunity and epitope spreading.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 11, 2023
- Source ID
- 10.1038/s41467-023-37874-2
Entities
People
- Ailin Zhang
- Annabelle Tsao
- Colm M. Morrissey
- Dmytro Rudoy
- Gerardo Javier
- Huiyun Sun
- Ilsa M. Coleman
- John K Lee
- Jun Ishihara
- Koichi Sasaki
- Lauren Hitchcock
- Lawrence D. True
- Li-ting Wu
- Martine P. Roudier
- Michael C. Haffner
- Nikhil V. Kamat
- Peter S Nelson
- Radhika A. Patel
- Roman Gulati
- Sam Nutt
- Saul J Priceman
- Shivani Srivastava
- Tiffany E. Pariva
- Vipul Bhatia
Organizations
- Doris Duke Charitable Foundation
- Japan Society for the Promotion of Science
- National Cancer Institute
- Prostate Cancer Foundation
- United States Department of Defense
- United States Department of Health and Human Services